Manufacturer
ASTRAZENECA AB
Contents
Osimertinib
Indication
Locally advanced or metastatic EGFR T790 mutation positive non-small cell lung cancer whose disease has progressed on or after EGFR TKI therapy.
Instruction
May be taken with or without food: Take at the same time each day. Swallow whole do not crush/split/chew. For patients w/ swallowing difficulties, tab may be dispersed in 50 mL non-carbonated water & stir w/o crushing until dispersed. Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via nasogastric tube by using 15 mL for initial dispersion & 15 mL for residue rinses. The tube should be flushed w/ water after administration. Administer soln w/in 30 min after prep.
Drug interaction
Decreased exposure by strong (eg, phenytoin, rifampicin, carbamazepine) & moderate (eg, bosentan, efavirenz, etravirine, modafinil) CYP3A4 inducers. Increased exposure of BCRP substrates. Increased AUC & Cmax of rosuvastatin. Decreased AUC & Cmax of simvastatin. Not to be used w/ St. John's wort.
Malaysia
